# US 2026/0146102 A1 · Methods for modulating regulatory t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0146102 A1
- Document ID: US20260146102A1
- Status: Published application
- Kind: A1
- Application number: 19/327,165
- Filed: 2025-09-12
- Published: 2026-05-28
- Earliest claimed: 2018-09-14
- Assignees: Universite de Lausanne
- Applicants: Universite de Lausanne
- Inventors: Ping-Chih Ho; Haiping Wang
- Web page: https://patentgrep.com/patent/US20260146102A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/381: having five-membered rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 39/001129: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure describes a novel approach that specifically modulates the activity and/or the number of intratumoral regulatory T (Treg) cells in a subject. Such an approach can be used to reduce the number of intratumoral T regulatory cells in a subject as well as to inhibit tumor growth in a subject having a cancer without eliciting autoimmune responses.

## Claims

### Claim 1

A method of reducing the number of intratumoral T regulatory cells in a subject in need thereof comprising administering to the subject an effective amount of a CD36 inhibitor.

### Claim 2

A method of reducing the number of intratumoral T regulatory cells in a subject in need thereof comprising administering to the subject an effective amount of a PPARβ inhibitor.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the intratumoral T regulatory cells are CD4+ cells.

### Claim 4

A method of increasing the number of intratumoral cytotoxic T-cells in a subject in need thereof comprising administering to the subject an effective amount of a CD36 inhibitor.

### Claim 5

A method of increasing the number of intratumoral cytotoxic T-cells in a subject in need thereof comprising administering to the subject an effective amount of a PPARβ inhibitor.

### Claim 6 (depends on 4, 5)

The method of claim 4 or 5, wherein the intratumoral cytotoxic T-cells are CD8+ cells.

### Claim 7 (depends on 1, 4)

The method of claim 1 or 4, wherein the CD36 inhibitor is an anti-CD36 antibody or a small molecule CD36 inhibitor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-CD36 antibody is a human antibody, a humanized antibody, a chimeric antibody, or a bispecific antibody.

### Claim 9 (depends on 7)

The method of claim 7, wherein the small molecule CD36 inhibitor is selected from the group consisting of AP-5258, AP5055, EP-80317, MPE-002, CHEML1789142, CHEML1789302, CHEML1789297, CHEML1789141, CHEML1789270, CHEML1789308.

### Claim 10 (depends on 1, 4)

The method of any one of claims 1, 4, and 7-9, wherein the CD36 inhibitor is administered intratumorally, intravenously, subcutaneously, intraosseously, orally, transdermally, in sustained release, in controlled release, in delayed release, as a suppository, or sublingually.

### Claim 11 (depends on 2, 5)

The method of claim 2 or 5, wherein the PPARβ inhibitor is an anti-PPARβ antibody or a small molecule PPARβ inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anti-PPARβ antibody is a human antibody, a humanized antibody, a chimeric antibody, or a bispecific antibody.

### Claim 13 (depends on 11)

The method of claim 11, wherein the small molecule PPARβ inhibitor is selected from the group consisting of FH535, GSK0660, GSK3787, PT-S58, PT-S77, and ST-247.

### Claim 14 (depends on 2, 5)

The method of any one of claims 2, 5, and 11-13, wherein the PPARβ inhibitor is administered intratumorally, intravenously, subcutaneously, intraosseously, orally, transdermally, in sustained release, in controlled release, in delayed release, as a suppository, or sublingually.

### Claim 15

The method of any one of the preceding claims, further comprising administering to the subject an additional therapeutic agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein the additional therapeutic agent comprises an immune checkpoint modulator.

### Claim 17 (depends on 16)

The method of claim 16, wherein the immune checkpoint modulator comprises an antibody specific for CTLA-4, PD-1, PD-L1, PD-L2, killer immunoglobulin receptor (KIR), LAG3, B7-H3, B7-H4, TIM3, A2aR, CD40L, CD27, OX40, 4-IBB, TCR, BTLA, ICOS, CD28, CD80, CD86, ICOS-L, B7-H4, HVEM, 4-1BBL, OX40L, CD70, CD40, and GALS.

### Claim 18 (depends on 15)

The method of claim 15, wherein the additional therapeutic agent comprises an anti-PD-1 mAb, an anti-CTLA4 mAb, or a combination thereof.

### Claim 19

The method of any one of the preceding claims, wherein the subject has cancer.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cancer is selected from the group consisting of oral cancer, oropharyngeal cancer, nasopharyngeal cancer, respiratory cancer, urogenital cancer, gastrointestinal cancer, central or peripheral nervous system tissue cancer, an endocrine or neuroendocrine cancer or hematopoietic cancer, glioma, sarcoma, carcinoma, lymphoma, melanoma, fibroma, meningioma, brain cancer, oropharyngeal cancer, nasopharyngeal cancer, renal cancer, biliary cancer, pheochromocytoma, pancreatic islet cell cancer, Li-Fraumeni tumors, thyroid cancer, parathyroid cancer, pituitary tumors, adrenal gland tumors, osteogenic sarcoma tumors, multiple neuroendocrine type I and type II tumors, breast cancer, lung cancer, head and neck cancer, prostate cancer, esophageal cancer, tracheal cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer, and skin cancer.

### Claim 21

A method of inhibiting tumor growth in a subject having a cancer, comprising administering to the subject a therapeutically effective amount of a CD36 inhibitor alone or in combination with an additional therapeutic agent.

### Claim 22

A method of inhibiting tumor growth in a subject having a cancer, comprising administering to the subject a therapeutically effective amount of a PPARβ inhibitor alone or in combination with an additional therapeutic agent.

### Claim 23 (depends on 21)

The method of claim 21, wherein the CD36 inhibitor is an anti-CD36 antibody or a small molecule CD36 inhibitor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the anti-CD36 antibody is a human antibody, a humanized antibody, a chimeric antibody, or a bispecific antibody.

### Claim 25 (depends on 23)

The method of claim 23, wherein the small molecule CD36 inhibitor is selected from the group consisting of AP-5258, AP5055, EP-80317, MPE-002, CHEML1789142, CHEML1789302, CHEML1789297, CHEML1789141, CHEML1789270, CHEML1789308.

### Claim 26 (depends on 21, 23, 24, 25)

The method of any one of claims 21 and 23 to 25, wherein the CD36 inhibitor is administered intratumorally, intravenously, subcutaneously, intraosseously, orally, transdermally, in sustained release, in controlled release, in delayed release, as a suppository, or sublingually.

### Claim 27 (depends on 22)

The method of claim 22, wherein the PPARβ inhibitor is an anti-PPARβ antibody or a small molecule PPARβ inhibitor.

### Claim 28 (depends on 27)

The method of claim 27, wherein the anti-PPARβ antibody is a human antibody, a humanized antibody, a chimeric antibody, or a bispecific antibody.

### Claim 29 (depends on 27)

The method of claim 27, wherein the small molecule PPARβ inhibitor is selected from the group consisting of FH535, GSK0660, GSK3787, PT-S58, PT-S77, and ST-247.

### Claim 30 (depends on 22, 27, 28, 29, 30)

The method of any one of claims 22 and 27 to 30, wherein the CD3 inhibitor is administered intratumorally, intravenously, subcutaneously, intraosseously, orally, transdermally, in sustained release, in controlled release, in delayed release, as a suppository, or sublingually.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21 to 30, wherein the additional therapeutic agent comprises an immune checkpoint modulator.

### Claim 32 (depends on 31)

The method of claim 31, wherein the immune checkpoint modulator comprises an antibody specific for such as an antibody specific for CTLA-4, PD-1, PD-L1, PD-L2, killer immunoglobulin receptor (KIR), LAG3, B7-H3, B7-H4, TIM3, A2aR, CD40L, CD27, OX40, 4-IBB, TCR, BTLA, ICOS, CD28, CD80, CD86, ICOS-L, B7-H4, HVEM, 4-1BBL, OX40L, CD70, CD40, and GALS.

### Claim 33 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 21 to 32, wherein the cancer is selected from the group consisting of oral cancer, oropharyngeal cancer, nasopharyngeal cancer, respiratory cancer, urogenital cancer, gastrointestinal cancer, central or peripheral nervous system tissue cancer, an endocrine or neuroendocrine cancer or hematopoietic cancer, glioma, sarcoma, carcinoma, lymphoma, melanoma, fibroma, meningioma, brain cancer, oropharyngeal cancer, nasopharyngeal cancer, renal cancer, biliary cancer, pheochromocytoma, pancreatic islet cell cancer, Li-Fraumeni tumors, thyroid cancer, parathyroid cancer, pituitary tumors, adrenal gland tumors, osteogenic sarcoma tumors, multiple neuroendocrine type I and type II tumors, breast cancer, lung cancer, head and neck cancer, prostate cancer, esophageal cancer, tracheal cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer, and skin cancer.
